Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health

Q1 Engineering

Nanobiomedicine Pub Date : 2015-01-01 DOI:10.5772/61114

E. Miller, H. Sikes

{"title":"Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health","authors":"E. Miller, H. Sikes","doi":"10.5772/61114","DOIUrl":null,"url":null,"abstract":"Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.","PeriodicalId":56366,"journal":{"name":"Nanobiomedicine","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5772/61114","citationCount":"43","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanobiomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/61114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 43

Abstract

Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.

查看原文本刊更多论文

在全球卫生领域解决发展和采用快速诊断测试的障碍

在资源有限的环境中，免疫层析快速诊断试验(rdt)已显示出作为即时诊断试验的巨大潜力。最值得注意的是，疟疾快速诊断疗法已经达到了前所未有的技术成熟度和市场渗透率，现在被认为是对标准疟疾显微诊断方法的重要补充。然而，针对其他传染病的快速诊断疗法的技术发展，以及在全球卫生界将其作为一种核心诊断方式的采用，一直受到一些现存挑战的阻碍。这些问题包括技术和生物问题，例如需要更好的亲和剂和疾病生物标志物，以及社会、基础设施、监管和经济障碍，这些障碍都减缓了它们的采用并削弱了它们的影响。为了使免疫层析RDT格式成功地适应其他疾病目标，看到广泛分布，并改善全球范围内患者的临床结果，必须确定和解决这些挑战，并且全球卫生界必须参与倡导更广泛地使用RDT。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanobiomedicine Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

6.80

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered. All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles. Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to: Nanoscale-structured biomaterials, Nanoscale bio-devices, Nanoscale imaging, Nanoscale drug delivery, Nanobiotechnology, Nanorobotics, Nanotoxicology, Nanoparticles, Nanocarriers, Nanofluidics, Nanosensors (nanowires, nanophotonics), Nanosurgery (dermatology, gastroenterology, ophthalmology, etc), Nanocarriers commercialization of nanobiomedical technologies, Market trends in the nanobiomedicine space, Ethics and regulatory aspects of nanobiomedicine approval, New perspectives of nanobiomedicine in clinical diagnostics, BioMEMS, Nano-coatings, Plasmonics, Nanoscale visualization.